Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
18 févr. 2021 07h30 HE
|
Flexion Therapeutics, Inc.
First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety dataCompany to expand FX201 low dose and mid dose cohorts...
National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
01 févr. 2021 09h00 HE
|
Flexion Therapeutics, Inc.
CHICAGO and BURLINGTON, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion Therapeutics Inc. today announced a new partnership to raise...
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
13 janv. 2021 07h00 HE
|
Flexion Therapeutics, Inc.
Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 millionFull-year 2020 net sales estimated to be...
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
07 janv. 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
07 déc. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 déc. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 nov. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
05 nov. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
04 nov. 2020 16h01 HE
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
29 oct. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S....